Core Viewpoint - The company announced that its subsidiary, Puan Pharmaceutical, received approval from the National Medical Products Administration for two supplementary applications for clinical trials of the drug Brivaracetam oral film in 0.5mg and 1mg specifications, which are intended for the treatment of schizophrenia [1] Group 1 - The approval includes the addition of new specifications for the clinical trial of Brivaracetam oral film [1] - The clinical trial work will continue following the approval, as per the requirements of China's drug registration laws and regulations [1] - The drug must undergo clinical trials and receive further review and approval from the National Medical Products Administration before it can be produced and marketed [1]
陇神戎发：获得布瑞哌唑口溶膜药物临床试验补充申请批准通知书